Streetbeat News

Regulatory

FXI

SPY

Five Republican Senators have urged the Biden Administration to limit travel between the U.S. and China due to a rise in cases of respiratory illness in China. They believe that restricting travel could help prevent the spread of diseases from China to the U.S. The request comes amid heightened concerns over global health and the potential impact on international travel and relations.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 3:43 pm

SPY

Fed's Goolsbee warns that economic shocks can still occur and past instances of soft landings have been disrupted by such unexpected events. This statement suggests that while the economy may be on a path to a soft landing, unforeseen circumstances could still pose risks.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 3:16 pm

BIOR

Biora Therapeutics Inc (NASDAQ:BIOR) stock is trading higher after the FDA cleared its IND application for BT-600, a drug/device combination for treating moderate to severe ulcerative colitis. The NaviCap device, used for targeted delivery to the colon, will be evaluated in a phase 1 trial for safety, pharmacokinetics, and pharmacodynamics. Studies have shown the device's accurate localization and delivery without fasting or food restrictions. BIOR shares have risen 14.50% to $1.42.

Portfolio Pulse from Vandana Singh

December 01, 2023 | 3:01 pm

GSK

GlaxoSmithKline (GSK) has reached an agreement with the European Medicines Agency (EMA) to immediately discontinue the manufacturing of Integrilin, as reported by Reuters.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 2:31 pm

SPY

Punchbowl Reporter Jake Sherman reports that Speaker Johnson will vote AGAINST expelling Mr. SantosNY.

Portfolio Pulse from Charles Gross

December 01, 2023 | 2:18 pm

APLS

Apellis Pharmaceuticals updated the USPI for SYFOVRE to include rare events of retinal vasculitis in patients treated with the drug. The estimated rate of these events is 0.01% per injection for the treatment of geographic atrophy secondary to age-related macular degeneration. This update was made in collaboration with the FDA and follows more than 120,000 injections administered as of November 18, 2023.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 1:51 pm

JFBR

NEXI

PATH

Neximmune (NEXI) shares surged 400% premarket after the company's board approved a plan for liquidation and dissolution on November 2. Jeffs' Brands (JFBR) stock jumped 143% following regulatory approvals in Spain and The Netherlands to commence sales. UiPath (PATH) shares increased by 18% after reporting better-than-expected Q3 financial results.

Portfolio Pulse from ryanfaloona@benzinga.com

December 01, 2023 | 1:44 pm

GMFI

Aetherium Acquisition Corp. (GMFI) has received a Staff Determination Letter from Nasdaq indicating potential delisting due to non-compliance with minimum market value and shareholder count requirements. The company failed to maintain the required $50 million market value and 400 shareholders. It also did not file Forms 10-Q for the periods ending March 31, June 30, and September 30, 2023. GMFI plans to appeal the decision and has taken steps to regain compliance, including transitioning accounting services and working with EF Hutton to increase shareholder count.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 1:33 pm

LGND

Palvella Therapeutics and Ligand Pharmaceuticals (NASDAQ:LGND) have expanded their strategic partnership to accelerate Phase 3 development of QTORIN rapamycin for Microcystic Lymphatic Malformations (Microcystic LMs). Palvella received a $5 million upfront payment from Ligand, which also increased its tiered royalty on worldwide sales of QTORIN rapamycin to 8.0–9.8%. Ligand has an option to acquire a single-digit royalty on future topical products from Palvella's QTORIN platform. QTORIN rapamycin has potential to be the first FDA-approved therapy for Microcystic LMs, with over 30,000 diagnosed patients in the U.S. The FDA granted Breakthrough Therapy Designation to the drug in November 2023.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 1:23 pm

AMAT

Applied Materials, Inc. has received validation from the Science Based Targets initiative (SBTi) for its science-based emissions reduction targets. The company has committed to reducing its absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 50% by fiscal year 2030, using fiscal year 2019 as the base year.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 12:41 pm